Table 2.
Landmark model‐predicted percentage of PASI75 and PASI90 responders for systemic treatments in patients with moderate to severe psoriasis at 12 weeks
| Drug | Clinical dose | Landmark model‐predicted PASI responders (%) | Landmark model‐predicted difference from placebo (%) | ||
|---|---|---|---|---|---|
| PASI75 | PASI90 | PASI75 | PASI90 | ||
| TNF‐α inhibitor | |||||
| Adalimumab | 40 mg Q2W | 64.9 (59.9, 69.3) | 37.9 (32.9, 42.9) | 59.5 (54.5, 63.8) | 36.3 (31.1, 41.2) |
| Certolizumaba | 200 mg Q2W | 73.5 (55.1, 83.2) | 48.2 (28.6, 62.7) | 68.0 (49.7, 77.7) | 46.5 (26.9, 60.8) |
| Etanercept | 25 mg BIW | 37.4 (34.3, 41.1) | 16.1 (14.1, 18.2) | 31.9 (28.8, 35.7) | 14.3 (12.4, 16.6) |
| Etanercept | 50 mg BIW | 54.0 (51.3, 56.7) | 27.6 (25.4, 30.1) | 48.4 (45.8, 51.5) | 26.0 (23.7, 28.4) |
| Infliximab | 5 mg/kg Q8W | 77.0 (72.2, 80.7) | 53.0 (46.1, 58.4) | 71.6 (66.6, 75.1) | 51.3 (44.4, 56.8) |
| IL‐17 inhibitor | |||||
| Brodalumaba | 210 mg Q2W | 81.2 (77.0, 84.4) | 59.3 (52.4, 64.4) | 75.8 (71.5, 79.0) | 57.7 (50.7, 62.9) |
| Ixekizumab | 80 mg Q4W | 88.2 (86.8, 89.5) | 71.7 (69.1, 74.6) | 82.7 (81.2, 84.1) | 70.0 (67.2, 72.9) |
| Secukinumab | 150 mg QM | 75.7 (73.0, 78.4) | 51.1 (47.2, 55.2) | 70.2 (67.5, 73.1) | 49.4 (45.6, 53.4) |
| IL‐12/23 inhibitor | |||||
| Briakinumabb | 100 mg Q4W | 80.8 (78.4, 82.6) | 58.4 (54.9, 61.9) | 75.2 (72.9, 77.3) | 56.8 (53.3, 60.4) |
| Ustekinumab | 45 mg Q12W | 70.3 (67.8, 72.6) | 43.6 (40.8, 46.7) | 64.9 (62.3, 67.3) | 41.9 (39.0, 45.1) |
| Dihydrofolate reductase inhibitor | |||||
| Methotrexate | 18 mg QW | 36.4 (32.7, 40.6) | 15.5 (13.2, 18.1) | 31.0 (27.2, 35.4) | 13.8 (11.5, 16.3) |
| JAK inhibitor | |||||
| Tofacitiniba | 5 mg BID | 35.2 (30.9, 39.1) | 14.8 (12.4, 17.1) | 29.7 (25.2, 33.7) | 13.1 (10.7, 15.5) |
| Tofacitiniba | 10 mg BID | 53.8 (47.0, 58.7) | 27.5 (22.1, 31.8) | 48.2 (41.7, 53.2) | 25.8 (20.7, 30.1) |
| Baricitiniba | 10 mg QD | 33.2 (21.4, 49.0) | 13.6 (8.05, 23.7) | 27.5 (15.7, 43.9) | 11.9 (6.28, 22.1) |
| Vitamin A analog | |||||
| Acitretin | 30 mg QD | 25.0 (16.1, 36.7) | 9.57 (5.55, 15.7) | 19.6 (10.6, 31.5) | 7.92 (3.80, 14.1) |
| CD2 antagonist | |||||
| Alefacept | 10 mg QW | 22.7 (15.0, 30.3) | 8.39 (5.23, 12.3) | 17.2 (9.54, 24.9) | 6.61 (3.53, 10.5) |
| PDE4 inhibitor | |||||
| Apremilast | 30 mg BID | 26.8 (23.2, 31.8) | 10.3 (8.52, 12.8) | 21.3 (17.6, 26.1) | 8.60 (6.78, 11.1) |
| Calcineurin inhibitor | |||||
| Ciclosporin | 2.5–5 mg/kg/d | 46.7 (36.9, 56.5) | 22.1 (16.0, 29.6) | 41.2 (31.6, 50.8) | 20.4 (14.3, 27.8) |
Values presented are mean (90% confidence intervals) and were generated assuming a typical weight of 90 kg.
a
Investigational.
b
Discontinued. All other drugs are approved.
BID, twice daily; BIW, twice weekly; CD2, T lymphocyte; IL, interleukin; JAK, Janus kinase; PASI75/90, ≥ 75% or ≥ 90% reduction from baseline Psoriasis Area and Severity Index score; PDE4, phosphodiesterase 4; QD, once daily; QM, once monthly; QW, once weekly; Q2W, once every 2 weeks; Q4W, once every 4 weeks; Q8W, once every 8 weeks; Q12W, once every 12 weeks; TNF, tumor necrosis factor.